Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 9/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.48 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.48 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.48 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | CHRNB2 | P17787 | 4/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 4/20 | 0.44 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 0.42 |
| ▸ | HTR3B | O95264 | 4/20 | 0.42 |
| ▸ | HTR3A | P46098 | 4/20 | 0.42 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 0.42 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HTR1D | P28221 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3045513 | 0.86 | ADRB1 (0.57) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL6973293 | 0.84 | ADRB1 (0.55) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL11551435 | 0.84 | ADRB1 (0.55) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| Hydrochloric Acid SCHEMBL11550261 | 0.84 | ADRB1 (0.55) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL12496993 | 0.82 | CHRNB2 (0.40) | CHRNB2CHRNA4ALDH1A1TP53HTT | |
| SCHEMBL18278772 | 0.78 | ADRB1 (0.56) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL19457821 | 0.78 | ADRB1 (0.56) | ADRB1CHRM2CHRM4CHRM1CHRM3 | |
| SCHEMBL15365518 | 0.78 | NPC1 (0.42) | HTR3EHTR3BHTR3AHTR3DHTR3C | |
| SCHEMBL3761215 | 0.78 | MEN1 (0.44) | ALDH1A1TP53CYP1A2HTT | |
| SCHEMBL7229947 | 0.78 | ADRB1 (0.75) | ADRB1CHRM2CHRM4CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622905-B2 | Aryl pladienolides for the treatment of neoplastic disorders | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2026-05-12 | — | — | US | disclosed |
| CN-117285502-A | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-12-26 | — | — | CN | disclosed |
| CN-112368270-B | Pladienolide derivatives as spliceosome targeting agents for the treatment of cancer | 卫材R&D管理有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-09-28 | — | — | US | disclosed |
| US-11679107-B2 | Certain aryl pladienolide compounds and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-06-20 | — | — | US | disclosed |
| US-11679107-B2 | Certain aryl pladienolide compounds and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-06-20 | — | — | US | disclosed |
| US-11679107-B2 | Certain aryl pladienolide compounds and methods of use | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-06-20 | — | — | US | disclosed |
| US-20210177837-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2021-06-17 | — | — | US | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-8530480-B2 | Substituted pyrimidinyl-amines as protein kinase inhibitors | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-10 | — | — | US | disclosed |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2013-09-05 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-11-25 | — | — | US | disclosed |
| EP-2200436-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | The Scripps Research Institute (US) | 2010-06-30 | — | — | EP | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
| WO-2009032861-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11679107-B2 | Certain aryl pladienolide compounds and methods of use | PLAAT5, PLAAT3, SNRPE | ADRB1 4117/4885CHRM2 4851/4885CHRM4 4845/4885 |
| US-12622905-B2 | Aryl pladienolides for the treatment of neoplastic disorders | SF3B1, SF3B5, SF3B2 | ADRB1 3332/4885CHRM2 4684/4885CHRM4 4779/4885 |
| US-20230301990-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | ADRB1 4266/4885CHRM2 4845/4885CHRM4 4835/4885 |
| US-20130231336-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | ADRB1 2017/4885CHRM2 4841/4885CHRM4 4804/4885 |
| US-20100298312-A1 | SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS | MAP3K20, MAP3K5, MAP3K7 | ADRB1 2017/4885CHRM2 4841/4885CHRM4 4804/4885 |
| US-20210177837-A1 | CERTAIN ARYL PLADIENOLIDE COMPOUNDS AND METHODS OF USE | PLAAT5, PLAAT3, PLAAT4 | ADRB1 4120/4885CHRM2 4849/4885CHRM4 4846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.